Delving into the Latest Updates on Personalized Cancer Vaccine(Stemirna Therapeutics) with Synapse

Overview

Basic Info

Drug Type

Personalized antigen vaccine, Therapeutic vaccine, mRNA vaccine

Synonyms

Personalized Cancer Vaccine (PCV), Personalized mRNA tumour vaccine(Stemirna Therapeutics Co. Ltd.), mRNA-based personalized Cancer Vaccine

+ [6]

Target-

Mechanism

Gene transference, Immunostimulants

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication

Adenocarcinoma of large intestineAdvanced Esophageal Squamous Cell CarcinomaAdvanced Lung Non-Small Cell Carcinoma+ [4]

Originator Organization

Stemirna Therapeutics Co., Ltd.Startup

Active Organization

Stemirna Therapeutics Co., Ltd.Startup

Inactive Organization-

Drug Highest PhaseClinical

First Approval Date-

Regulation-

Login to view timeline

This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.

Start Date20 Jul 2023

Sponsor / Collaborator

Stemirna Therapeutics Co., Ltd.Startup

NCT05198752 / RecruitingPhase 1

A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours

This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.

Start Date18 Mar 2022

Sponsor / Collaborator

Stemirna Therapeutics Co., Ltd.Startup

NCT03908671 / RecruitingNot Applicable

Clinical Trial on the Safety and Efficacy of Neoantigen Antigen mRNA Tumor Vaccine in the Treatment of Advanced Esophageal Cancer and Non-small Cell Lung Cancer

A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung cancer

Start Date18 Oct 2019

Sponsor / Collaborator

Stemirna Therapeutics Co., Ltd.Startup

[+1]

100 Clinical Results associated with Personalized Cancer Vaccine(Stemirna Therapeutics)

Login to view more data

100 Translational Medicine associated with Personalized Cancer Vaccine(Stemirna Therapeutics)

Login to view more data

100 Patents (Medical) associated with Personalized Cancer Vaccine(Stemirna Therapeutics)

Login to view more data

44

Literatures (Medical) associated with Personalized Cancer Vaccine(Stemirna Therapeutics)

01 Jul 2024·Nature Reviews Clinical Oncology

Cancer mRNA vaccines: clinical advances and future opportunities

Review

Author: Mitchell, Duane A ; Nair, Smita K ; Boczkowski, David ; Sayour, Elias J

mRNA vaccines have been revolutionary in terms of their rapid development and prevention of SARS-CoV-2 infections during the COVID-19 pandemic, and this technology has considerable potential for application to the treatment of cancer. Compared with traditional cancer vaccines based on proteins or peptides, mRNA vaccines reconcile the needs for both personalization and commercialization in a manner that is unique to each patient but not beholden to their HLA haplotype. A further advantage of mRNA vaccines is the availability of engineering strategies to improve their stability while retaining immunogenicity, enabling the induction of complementary innate and adaptive immune responses. Thus far, no mRNA-based cancer vaccines have received regulatory approval, although several phase I-II trials have yielded promising results, including in historically poorly immunogenic tumours. Furthermore, many early phase trials testing a wide range of vaccine designs are currently ongoing. In this Review, we describe the advantages of cancer mRNA vaccines and advances in clinical trials using both cell-based and nanoparticle-based delivery methods, with discussions of future combinations and iterations that might optimize the activity of these agents.

01 Mar 2024·Vaccine: X

Patterns of basic pneumococcal conjugated vaccine coverage in Ethiopia from 2015 to 2018; further analysis of Ethiopian DHS (2016–2019)

Review

Author: Balis, Bikila ; Birhanu, Abdi ; Motuma, Aboma ; Getachew, Tamirat ; Deressa, Alemayehu ; Gamachu, Mulugeta ; Tolera, Moti ; Abdurahman, Dureti ; Mohammed, Fethia ; Mussa, Ibsa ; Jibro, Usmael ; Demissie Regassa, Lemma ; Negash, Abraham

BackgroundGeographic variation is crucial in spotting performance gaps in immunization programs, including the Pneumococcal Conjugated Vaccine (PCV). This will help speed up targeted vaccination and disease elimination programs in resource-limited countries. Thus, this study aimed to investigate the geographic variation and determinants of PCV vaccination coverage among children aged under five years old in Ethiopia.MethodsThis analysis was carried out based on the 2016 and 2019 nationally representative Ethiopia Demographic and Health Survey (EDHS). We included two surveys of 10,640 children aged 12-23 months. The spatial analysis also covered 645 and 305 clusters with geographical information for both 2016 and 2019, respectively. We explored the spatial distribution, global spatial autocorrelation, spatial interpolation, and Stats Can windows of children with PCV-3 vaccination. P-values were generated using 999 Monte Carlo simulations to identify statistically significant clusters. To understand the coverage of PCV-3 in all areas of the country, we employed the ordinary Kriging interpolation method to estimate the coverage in unsampled areas. We also used hierarchical multivariate logistic regression to identify the factors associated with the utilization of the PCV vaccine (full vaccination).ResultsExcept for Addis Ababa, children in all regions have lower odds of receiving all three PCV vaccines compared to the Tigray region. Residence, sex of a child, mother's literacy status, household wealth index, and place of delivery were significant factors associated with receiving the third dose of PCV. Spatial analysis also showed the Somali and Afar regions had the lowest coverage, while the Addis Ababa and Tigray regions had higher coverage in both surveys.ConclusionEven though the coverage of the full PCV vaccine improved from 2016 to 2019, variation was observed among regions and between rural and urban areas. The wealth index and educational status of mothers were the most important determinants of PCV vaccine utilization. Hence, the mass campaign might boost coverage in nomadic and semi-nomadic regions and rural areas. Similarly, programs that narrow the gap due to low socioeconomic differences should be formulated and implemented to increase uptake and general coverage.

01 Jan 2024·Acta Pharmaceutica Sinica B

Advanced nano-based strategies for mRNA tumor vaccine

Review

Author: Sun, Tao ; Chen, Qinjun ; Zhang, Tong ; Qu, Yangqi ; Xu, Jingjing ; Jiang, Chen

100 Deals associated with Personalized Cancer Vaccine(Stemirna Therapeutics)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	AU	Stemirna Therapeutics Co., Ltd.Startup	18 Mar 2022
Advanced Malignant Solid Neoplasm	Phase 1	AT	Stemirna Therapeutics Co., Ltd.Startup	18 Mar 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 1	CN	Stemirna Therapeutics Co., Ltd.Startup	24 Oct 2021
Esophageal Carcinoma	Phase 1	CN	Stemirna Therapeutics Co., Ltd.Startup	18 Oct 2019
Non-Small Cell Lung Cancer	Phase 1	CN	Stemirna Therapeutics Co., Ltd.Startup	18 Oct 2019
Adenocarcinoma of large intestine	Discovery	CN	Stemirna Therapeutics Co., Ltd.Startup	01 May 2018
Advanced Esophageal Squamous Cell Carcinoma	Discovery	CN	Stemirna Therapeutics Co., Ltd.Startup	01 May 2018
Pancreatic adenocarcinoma	Discovery	CN	Stemirna Therapeutics Co., Ltd.Startup	01 May 2018
stomach adenocarcinoma	Discovery	CN	Stemirna Therapeutics Co., Ltd.Startup	01 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03468244 (Pubmed \| Am J Cancer Res) Manual	Not Applicable	Advanced Esophageal Squamous Cell Carcinoma	1	Personalized mRNA vaccine	(udewuorkvd) = No grade 3 or higher drug-related adverse events were observed, except for grade 4 thrombocytopenia caused by PD-1 inhibitor treatment. wzbqlvzbgd (kobwpdagcm )	Positive	01 Jan 2024